Highbridge Capital Management’s Novavax NVAX Stock Holding History

Highbridge Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-575	Closed	-$84K	–	1577
2016 Q2	$84K	Sell	575 -740	-56%	-$84.8K	﹤0.01%	1317
2016 Q1	$135K	Sell	1,315 -25	-2%	-$2.68K	﹤0.01%	1387
2015 Q4	$225K	Buy	+1,340	New	+$206K	﹤0.01%	1292
2014 Q2	–	Sell	-720	Closed	-$65K	–	1229
2014 Q1	$65K	Buy	+720	New	+$80.4K	﹤0.01%	1000

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's NVAX Position: Q3 2015 in Review

Highbridge Capital Management sold out of Novavax (NVAX) in Q3 2015, closing a stake of 10,446 shares — an estimated $2.33M sold.

Highbridge Capital Management first reported a position in NVAX in Q1 2014 and held it in 4 quarters. The position peaked at $2.33M in Q2 2015. 190 funds tracked by Wall St. Rank hold NVAX as of Q3 2015.

Highbridge Capital Management reported no remaining Novavax position as of Q3 2015 after selling out during the quarter.
Highbridge Capital Management sold 10,446 Novavax shares in Q3 2015, an estimated $2.33M.
Highbridge Capital Management first reported a position in Novavax in Q1 2014 and held it in 4 quarters.
Highbridge Capital Management's Novavax position peaked at $2.33M in Q2 2015.
190 funds tracked by Wall St. Rank held Novavax as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.